Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
NCT06909253 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2026-05-15
Summary
The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.
Conditions
- Myasthenia Gravis, Generalized
Interventions
- DRUG
-
Ravulizumab
Ravulizumab, concentrate for solution for infusion
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-05-15
- Primary Completion
- 2029-12-31
- Completion
- 2029-12-31
- FDA Drug
- Yes
Countries
- Poland
Study Locations
More Related Trials
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
NCT03315130 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
NCT04833894 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
NCT03669588 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis
NCT03165435 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
NCT06909214 ·Status: RECRUITING ·Phase: PHASE4
-
Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis
NCT06688253 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
NCT00619671 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
NCT04115293 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
NCT06392386 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
NCT02473952 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
NCT03772587 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
NCT05868837 ·Status: RECRUITING ·Phase: PHASE3
-
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
NCT06607627 ·Status: RECRUITING ·Phase: PHASE3
-
Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis
NCT02609022 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
NCT07250750 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
NCT03052751 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
NCT03896295 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
NCT02965573 ·Status: COMPLETED ·Phase: PHASE2
-
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
NCT07247279 ·Status: RECRUITING
-
A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
NCT03770403 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
NCT04980495 ·Status: COMPLETED ·Phase: PHASE3
-
Disease-Modifying Treatments for Myasthenia Gravis
NCT03490539 ·Status: COMPLETED